|
IL139400A0
(en)
*
|
2000-11-01 |
2001-11-25 |
Yeda Res & Dev |
Long-acting cytokine derivatives and pharmaceutical compositions comprising them
|
|
AU2002239384B2
(en)
*
|
2000-12-13 |
2007-01-11 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
EP1446103B1
(en)
*
|
2001-10-19 |
2015-12-23 |
Idexx Laboratories, Inc. |
Injectable compositions for the controlled delivery of pharmacologically active compound
|
|
US6946137B2
(en)
*
|
2001-10-19 |
2005-09-20 |
Idexx Laboratories, Inc. |
Methods for the controlled delivery of pharmacologically active compounds
|
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
|
BE1015608A6
(fr)
*
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
|
JP4033382B2
(ja)
*
|
2002-04-08 |
2008-01-16 |
久光製薬株式会社 |
インスリン投与装置
|
|
WO2004064972A2
(en)
*
|
2003-01-16 |
2004-08-05 |
Hk Pharmaceuticals, Inc. |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
PL1620118T3
(pl)
*
|
2003-04-08 |
2014-11-28 |
Yeda Res & Dev |
Leki odwracalnie pegylowane
|
|
DK1615632T3
(da)
*
|
2003-04-17 |
2007-04-10 |
Jallal Messadek |
Flydende orale formularer for kontrolleret udskillelse af betain
|
|
WO2005012347A2
(en)
|
2003-08-05 |
2005-02-10 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
BE1016128A6
(fr)
*
|
2004-07-22 |
2006-03-07 |
Messadek Jallal |
Combinaisons therapeutiques
|
|
US7282487B2
(en)
*
|
2004-10-28 |
2007-10-16 |
Idexx Laboratories |
Method for treating bacterial infections in horses or pigs with tilmicosin
|
|
WO2006050581A2
(en)
*
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
|
CN101180073A
(zh)
*
|
2005-04-27 |
2008-05-14 |
贾拉尔·梅萨德克 |
胰岛素组合
|
|
DK1969004T3
(da)
*
|
2005-12-28 |
2011-11-28 |
Novo Nordisk As |
Insulinsammensætninger og metode til at lave en sammensætning
|
|
US9034818B2
(en)
|
2007-06-13 |
2015-05-19 |
Novo Nordisk A/S |
Pharmaceutical formulations comprising an insulin derivative
|
|
WO2009065193A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Jallal Messadek |
Treatment of aspirin resistance with betaine and/or betaine enriched molasses
|
|
KR101755434B1
(ko)
|
2008-03-18 |
2017-07-10 |
노보 노르디스크 에이/에스 |
프로테아제 안정화되고, 아실화된 인슐린 유사체
|
|
CN102076331B
(zh)
|
2008-06-26 |
2013-12-18 |
普罗林科斯有限责任公司 |
具有可控的药物释放速率的前药和药物-大分子轭合物
|
|
WO2010033220A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Modified therapeutics peptides, methods of their preparation and use
|
|
WO2010033240A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
|
AU2009307729B2
(en)
|
2008-10-21 |
2015-09-17 |
Nektar Therapeutics |
Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-PEGylation)
|
|
BRPI0919946A2
(pt)
*
|
2008-10-30 |
2016-02-16 |
Novo Nordisk As |
tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
|
|
RU2011140219A
(ru)
|
2009-03-05 |
2013-04-10 |
Асцендис Фарма Ас |
Пролекарства интерферона альфа на носителе
|
|
WO2011013128A2
(en)
|
2009-07-31 |
2011-02-03 |
Yeda Research And Development Co. Ltd. |
Vectors for delivery of neurotherapeutics to the central nervous system
|
|
JP5977229B2
(ja)
*
|
2010-05-05 |
2016-08-24 |
プロリンクス リミテッド ライアビリティ カンパニー |
巨大分子共役体からの徐放
|
|
HRP20191793T1
(hr)
|
2010-10-27 |
2019-12-27 |
Novo Nordisk A/S |
Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
|
|
EP2490378B1
(en)
|
2011-02-18 |
2014-07-09 |
NTT DoCoMo, Inc. |
Apparatus and method for determining a control unit using feasibility requests and feasibility responses
|
|
US10166295B2
(en)
|
2011-06-02 |
2019-01-01 |
Opko Biologics Ltd. |
Pegylated OXM variants
|
|
BR112013030933A2
(pt)
|
2011-06-02 |
2018-04-24 |
Prolor Biotech Inc |
agonistas do receptor de glp-1/glucágon de ação prolongada
|
|
KR20150002777A
(ko)
|
2012-04-11 |
2015-01-07 |
노보 노르디스크 에이/에스 |
인슐린 제제
|
|
CN104684576B
(zh)
|
2012-06-04 |
2019-08-06 |
奥普科生物制品有限公司 |
聚乙二醇化的oxm变体
|
|
EP2869830B1
(en)
|
2012-07-09 |
2016-10-12 |
Novo Nordisk A/S |
Novel use of insulin derivatives
|
|
US10137172B2
(en)
|
2013-04-30 |
2018-11-27 |
Novo Nordisk A/S |
Administration regime
|
|
DK3554534T3
(da)
|
2016-12-16 |
2021-08-23 |
Novo Nordisk As |
Farmaceutisk sammensætning omfattende insulin
|
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
|
US12441776B2
(en)
|
2018-11-30 |
2025-10-14 |
Eirgen Pharma Ltd. |
Oxyntomodulin peptide analog formulations
|
|
US20200254065A1
(en)
|
2019-02-11 |
2020-08-13 |
Opko Biologics Ltd. |
Long-acting glp-2 analogs
|
|
US12343383B2
(en)
|
2019-07-12 |
2025-07-01 |
Novo Nordisk A/S |
High concentration insulin formulation
|
|
CN113773398B
(zh)
*
|
2020-06-10 |
2023-05-23 |
宁波鲲鹏生物科技有限公司 |
一种德谷胰岛素衍生物及其应用
|
|
CN117551008B
(zh)
*
|
2023-11-10 |
2025-10-17 |
沈阳药科大学 |
一种去铁胺偶联物及其制备方法和应用
|